Bariatric Times

MAY 2017

A peer-reviewed, evidence-based journal that promotes clinical development and metabolic insights in total bariatric patient care for the healthcare professional

Issue link:

Contents of this Issue


Page 22 of 28

22 News and Trends Bariatric Times • May 2017 p rofessionals, and 150 employers in the United States. To learn more about the study, please visit About Novo Nordisk. Novo N ordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help p eople with other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, New Jersey, Novo Nordisk Inc. has nearly 5 ,000 employees in the United States. For more information, visit CHILDHOOD OBESITY QUADRUPLES RISK OF DEVELOPING TYPE 2 DIABETES WASHINGTON, DC—Children with obesity face four times the risk of developing type 2 diabetes compared t o children with a body mass index (BMI) in the normal range, according to a study published in the Journal of the Endocrine Society. Both obesity and diabetes are epidemic health problems. Obesity affects about 12.7 million children and teens in the United States. The SEARCH for Diabetes in Youth study found 3,600 cases of type 2 diabetes were diagnosed in U.S. children and teens each year between 2002 and 2005, according to the Endocrine Society's Endocrine Facts and Figures report. The researchers who published the Journal of the Endocrine Society study found a similar trend in a large-scale analysis of diabetes and obesity rates among British children. "As the prevalence of obesity and being overweight has rapidly risen, an increasing number of children and young adults have been diagnosed with diabetes in the United Kingdom since the early 1990s," said the one of the study's authors, Ali Abbasi, M.D., Ph.D., of King's College London in London, U.K. "A child with obesity faces a four-fold greater risk of being diagnosed with diabetes by age 25 than a counterpart who is normal weight." The cohort study used electronic health records from one of the largest primary care databases worldwide, the U.K. Clinical Practice Research Datalink, to pull data from 375 general practices. The researchers examined BMI measurements, diabetes diagnosis records, and other data for 369,362 children between the ages of 2 and 15. Examining data recorded between 1994 and 2013, the researchers found 654 children and teenagers were diagnosed with type 2 diabetes and 1,318 were diagnosed with type 1 diabetes. Children and teenagers with obesity constituted nearly half of the type 2 diabetes cases—308 in all. The study found no association between obesity and increased i ncidence of type 1 diabetes, which is linked to an underlying autoimmune disorder. "Diabetes imposes a heavy burden on society because the condition is c ommon and costly to treat," Abbasi said. "Estimates indicate one in 11 adults has type 2 diabetes, or about 415 million people worldwide. Given that diabetes and obesity are p reventable from early life, our findings and other research will hopefully motivate the public and policymakers to invest and engage in diabetes prevention efforts." O ther authors of the study include: Dorota Juszczyk and Martin C. Gulliford of King's College London; and Cornelia HM van Jaarsveld of Radboud University Medical Center in Nijmegen, t he Netherlands. Gulliford was supported by the NIHR Biomedical Research Centre at Guy's and St. Thomas' NHS Foundation Trust and King's College L ondon. The study, "Body Mass Index and Incident Type 1 and Type 2 Diabetes in Children and Young Adults: A Retrospective Cohort Study," will be published online at lookup/doi/10.1210/js.2017-00044. The Endocrine Society launched the first issue of its Open Access scholarly publication the Journal of the Endocrine Society in January, marking the first time the Society has introduced a new journal under its ownership in nearly 30 years. The online-only format is specifically intended to rapidly publish emerging science on a variety of endocrinology topics. BARIATRIC ADVANTAGE RELEASES NEW WEIGHT MANAGEMENT PROBIOTIC ALISO VIEJO, California—Bariatric Advantage ® , a pioneer in science-based patient-focused nutrition for bariatric patients, announced the launch of FloraVantage ® Control, featuring Bifidobacterium lactis B-420 ™ , a promising probiotic for weight maintenance. FloraVantage Control offers healthcare practitioners a unique approach to help patients in their quest to sustain healthy weight following weight loss. * Bariatric surgery patients who have success losing weight frequently find that maintaining that weight loss can be quite challenging. As part of a multidisciplinary weight management program, FloraVantage Control may help individuals achieve body weight regulation by modifying gut microbiota composition, and promoting the production of beneficial gut metabolites and helping to improve gut integrity. 1–5* "Bariatric patients require lifelong care," said Bret Petkus, vice president of commercial operations for Bariatric Advantage. "FloraVantage Control is a promising tool that may provide long- t erm support to help maintain a healthy weight."* FloraVantage Control is specially designed to help support body weight regulation by delivering a targeted p robiotic: Bifidobacterium lactis B- 420. This unique strain clinically showed in a six-month clinical study to reduce body fat mass, body weight, waist circumference, and abdominal f at all compared to placebo.5* "This probiotic marks a significant step forward for the targeted use of specific probiotic strains in the long- term support of patients," said Dr. J ohn Morton, chief of bariatric surgery at Stanford University and past president of the American Society for Metabolic and Bariatric Surgery. "I am glad to see Bariatric Advantage c ontinue to bring innovative solutions to support bariatric professionals and the patients they treat." Learn more about FloraVantage Control at R ead the full release at ews. *These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. REFERENCES 1. Stenman LK, et al. EBioMedicine. 2016;13:190–200. 2. Amar J, Chabo C, Waget A, et al. EMBO Mol Med. 2011;3(9):559–572. 3. Putaala H, Salusjärvi T, Nordström M, et al. Res Microbiol. 2008;159(9- 10):692–698. 4. Stenman LK, Waget A, Garret C, et al. Beneficial Microbes. 2014;5(4):437–445. 5. Stenman LK, Waget A, Garret C, et al. Diabetol Metab Syndr. 2015;12(7):75. About Bariatric Advantage. Bariatric Advantage (, part of Metagenics, Inc., is a market-leading provider of targeted nutrition solutions to meet the micronutrient replacement needs of bariatric surgery patients. Founded in 2002, Bariatric Advantage markets and distributes its nutritional products primarily through the medical professional channel under the brand name Bariatric Advantage. In 2010, it was acquired by Metagenics, Inc.—a nutrigenomics and lifestyle medicine company dedicated to helping people live happier, healthier lives by realizing their genetic potential and operates as a strategic business unit of Metagenics. Bariatric Advantage maintains its offices in Aliso Viejo, Calif. VITAMIN A + HIGH-FAT DIET = INCREASED RISK FOR OBESITY, DIABETES Study Finds Changes in Gene Expression, Body Mass with Nutrient Intake in High-fat Diet CHICAGO, Illinois—Vitamin A is an e ssential nutrient that the human body needs to function properly. But new research presented today at the Experimental Biology 2017 meeting in Chicago suggests that normal levels of v itamin A within a high-fat diet can negatively affect expression of liver genes associated with glucose and fat metabolism. Researchers fed two groups of rats a high-fat diet for eight weeks. One group consumed normal amounts of vitamin A ("sufficient"), while the other group ate food that lacked the nutrient ("deficient"). The research t eam measured the rats' body mass (an indicator of concentration of body fat) each week. After six weeks, the deficient group had significantly lower body mass than the sufficient group, a t rend that continued through the end of the trial. Fat mass in the liver and the duct surrounding the testicles (epididymis) was also decreased in the deficient group. E xpression of a liver protein (Cytochrome P450 26A1) that regulates levels of retinoic acid—a by- product of vitamin A—was higher in the sufficient group. This protein is also involved in the metabolism of fat and cholesterol. The research team also found that expression of genes that control glucose metabolism and insulin signaling pathways were higher in rats that consumed sufficient amounts of vitamin A. These results suggest that vitamin A combined with a high-fat diet may lead to a higher body weight and increased risk of insulin resistance and diabetes. More research is needed to determine how vitamin A status affects humans. However, these findings may be another reminder about the dangers of consuming a high-fat diet. "Our study [implies] that we should be careful about vitamin A, especially [in] overweight or obese people," wrote Heqian Kuang, first author of the study. Heqian Kuang, a graduate student at the University of Tennessee, Knoxville, also presented "Dietary vitamin A intake affects the body mass gain and hepatic gene expression in rats fed a high-fat diet" in a poster session during the meeting. About Experimental Biology 2017. Experimental Biology is an annual meeting comprised of more than 14,000 scientists and exhibitors from six sponsoring societies and multiple guest societies. With a mission to share the newest scientific concepts and research findings shaping clinical advances, the meeting offers an unparalleled opportunity for exchange among scientists from across the United States and the world who represent dozens of scientific areas, from laboratory to translational to clinical research.

Articles in this issue

Links on this page

Archives of this issue

view archives of Bariatric Times - MAY 2017